Picture of Novartis AG logo

NOVN Novartis AG Cashflow Statement

0.000.00%
ch flag iconLast trade - 00:00
HealthcareConservativeLarge CapHigh Flyer

Annual cashflow statement for Novartis AG, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2019
December 31st
2020
December 31st
2021
December 31st
2022
December 31st
2023
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:ARSARSARSARSARS
Standards:
IFRS
IFRS
IFRS
IFRS
IFRS
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line7,1478,07124,0186,9558,572
Depreciation
Amortisation
Non-Cash Items3,3693,842-11,7144,4042,403
Discontinued Operations
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital-2,717-4,727-3,346-4,304-4,794
Change in Accounts Receivable
Change in Inventories
Change in Other Assets
Change in Accounts Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities13,62513,65015,07114,23614,458
Capital Expenditures-2,257-2,585-2,971-2,671-2,753
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items31-10,5977,1794,1398,349
Acquisition of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Change in Net Investments
Purchase of Investments
Sale of Intangible Assets
Other Investing Cash Flow
Cash from Investing Activities-2,226-13,1824,2081,4685,596
Financing Cash Flow Items3,307-19994553,478
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities-13,627-2,208-16,264-20,562-14,278
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash-2,159-1,4542,749-4,8905,876